DEBIOPHARM
Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based, biopharmaceutical company aiming to establish tomorrow’s standard-of-care to cure cancer and infectious diseases, today announced the signing of an exclusive licensing agreement with Genome & Company (http://genomecom.co.kr/), a publicly-traded, South Korea-based, biotechnology company focusing on discovery and development of novel target antibody therapeutics, for the development of antibody drug conjugates (ADCs) with first-in-class potential. The agreement offers Debiopharm exclusive global rights to develop ADCs combining specific Genome and Company antibodies with Debiopharm’s innovative linker technology, Multilink™, to create highly innovative therapeutic agents to outsmart hard-to-treat cancers.
ADCs are cutting-edge oncology therapeutics that combine three components: a monoclonal antibody, a stable linker and one or more potent cytotoxic payload. These targeted compounds identify and dock onto specific antigens on cancer cell surfaces and promote targeted delivery of toxic payloads to antigen-expressing cancer cells. This modality improves therapeutic effectiveness while diminishing systemic toxicity and side effects typically associated with conventional cancer treatments. This distinctive capacity to selectively eliminate cancer cells while preserving healthy tissues has granted visibility to ADCs within the pharmaceutical development community. With the ever-growing interest in ADC development, linker design has increasingly become a critical determining factor, as few linkers provide satisfactory stability required for specific and effective drug release.1
“Building on our fruitful collaboration with Genome & Company, the potential of developing this novel antibody family with our proprietary MultilinkTM cleavable linker technology is an exciting opportunity. We recognized that Genome’s innovative antibodies were the right fit for our development focus due to the novelty of the target and its expression in tumor types with high unmet needs” expressed Frederic Levy, Chief Scientific Officer. “This extended collaboration with Genome & Company’s antibody against a novel target represents our commitment to form strategic partnerships for the development of first-in-class and best-in-class ADCs leveraging our proprietary Multilink™ technology, offering unique linker characteristics that grant a higher stability and DAR, thereby optimizing treatment specificity and effectiveness.”
Debiopharm is focused on further expanding their ADC platform, exploring proprietary novel bispecific ADCs and potential game changing technologies such as novel payloads, dual payloads, and degraders, leveraging their solid drug development experience to accelerate ADC products to patients.
“This agreement represents our first out-license deal in the field of novel target anti-cancer therapy of Genome & Company, and we were able to achieve meaningful results in early preclinical stage based on our excellent research and development capabilities,” commented Yoo Seok Hong, CEO of Genome & Company. “We expect to show results from our subsequent pipeline of novel target anti-cancer drugs in the near future, leveraging this license deal.”
About Multilink™
Multilink™ is a new cleavable linker platform suited for multidrug attachment and compatible with any conjugation technology to produce ADCs with high DAR (drug-to-antibody ratio). This unique and innovative technology allows the loading of multiple payloads on an antibody for an enhanced therapeutic effect. This highly effective and well-tolerated linker platform is available for use by other specialty biotech or pharmaceutical companies to generate proprietary, clinical-stage ADCs.
Debiopharm’s ADC Portfolio
Our ADC portfolio consists of carefully selected targets with 1st-in-class or best-in-class potential, including Debio 1562M, a CD37-targeted ADC for the treatment of acute myeloid leukemia (AML) Myelodysplastic syndromes (MDS) and Debio 0532, an HER3-targeted ADC for solid tumors. Key partnerships also comprise options to in-licence bispecific antibodies targeting HER2-HER3 and HER3-EGFR along with other further undisclosed targets. Our ADCs are designed with MultiLinkTM proprietary cleavable linker technology, allowing both high DAR and high stability. Debio 1562M, the CD37 ADC with a novel DM1 derivative payload, represents our most advanced program, expected to reach the clinic in 2025. We are continuing to invest in our ADC platform, exploring potential game changing technologies such as novel and dual payloads or degraders, leveraging our solid development experience to accelerate ADC products to patients.
About Genome & Company
Genome & Company is a South Korean-based biotechnology company specializing in discovery and development of novel cancer target antibodies as stand-alone therapy and antibody-drug conjugate (ADC) applications. The company leverages its GNOCLE™ drug discovery and development platform, a unique bed-to-bench approach based on real-world clinical data. For more information, please refer to our website http://www.genomecom.co.kr
About Debiopharm
Debiopharm develops innovative therapies that target high unmet medical needs in oncology and infectious diseases. Bridging the gap between disruptive discovery products and international patient reach, we identify high-potential compounds and technologies for in-licensing, clinically demonstrate their safety and efficacy and then select large pharmaceutical commercialization partners to maximize patient access globally.
Visit us www.debiopharm.com
Follow us on X @DebiopharmNews at http://twitter.com/DebiopharmNews
Follow us on LinkedIn
References:
- Zheng Su et al. Acta Pharmaceutica Sinica B 2021;11(12):3889e3907
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240603093689/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ullevaal Stadium Among the First in the World to Install FIFA Quality Pro Certified LED Lighting System2.12.2025 15:15:00 CET | Press release
A newly installed, state-of-the-art LED lighting system at Ullevaal Stadium has transformed the playing, viewing, and entertainment experience for athletes and spectators, and has made Norway’s national stadium one of the few in the world with FIFA Quality Pro Certification. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251201171907/en/ The state-of-the-art TLC for LED® lighting system at Ullevaal Stadium has made Norway’s national stadium one of the few in the world with FIFA Quality Pro Certification. Home to Norway’s national football team, Ullevaal Stadium opened in 1926 and has a rich history of hosting significant sporting and entertainment events. When stadium ownership at the Football Association of Norway (NFF) decided to upgrade the venue’s lighting, they envisioned a system with the most advanced LED technology for the best possible playing, viewing, and entertainment experience. “Our main priorities for the new
Logical Intelligence Achieves 76 Percent on Putnam Benchmark, Highlighting Shift Beyond Large Language Models to Language-free, Mathematically Grounded Models2.12.2025 15:15:00 CET | Press release
Over the last decade, artificial intelligence (AI) has been largely built around large language models (LLMs). These systems are based on a language and guess words in a chain in the form of tokens. As a result, they frequently hallucinate and require vast compute and power infrastructure to solve tasks. The moment systems like public safety, national infrastructure, and industrial automation need logic, LLMs break and introduce safety risks. Token-free language independent models represent a new direction for AI. They do not predict words. They search for correct solutions and require less compute. Logical Intelligence is the first company building exclusively around mathematically derived, non autoregressive EBM (Energy Based Model) reasoning. Today, Logical Intelligence announced that its Aleph tool achieved a 76 percent score on the Putnam Benchmark, one of the most demanding mathematical reasoning tests in artificial intelligence. The benchmark measures a model’s ability to solve
MUSASHI JAPAN Launches “Gift Campaign 2025” - A Holiday Tradition Honoring Craftsmanship Through Meaningful Gifts2.12.2025 15:07:00 CET | Press release
MUSASHI JAPAN by TAIMATSU announces the return of its year-end celebration, Gift Campaign 2025, a seasonal tradition that transforms holiday shopping into an experience of appreciation, craftsmanship, and cultural generosity. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202812444/en/ Rather than focusing on discounts, MUSASHI embraces the philosophy that true value lies in tools that last and in the gestures that accompany them. This year’s campaign invites customers to discover gifts that enrich their craft in the kitchen, each thoughtfully chosen to support the longevity and performance of every Musashi blade. Inspired by the Japanese principle of omotenashi, the campaign offers customers tiered gifts based on their total purchase amount, ensuring that every contribution is met with gratitude and purpose. From December 2 to December 25, 2025, customers shopping in MUSASHI JAPAN stores will receive: Tier 1: Oil and Rus
Invisible IT Emerges as Workplace Transformation Evolves, Lenovo Research Finds2.12.2025 15:00:00 CET | Press release
Four out of five IT leaders say their systems can’t keep up and are turning to AI-powered automation to make IT seamless, predictive, and proactive. The next step in workplace transformation is invisible technology that fades into the background so that support is automated and seamless, according to a Lenovo global survey of IT leaders released today. Most employees only notice IT when it slows them down and interrupts processes. Invisible IT is the opposite. It means technology that anticipates needs, prevents issues before they happen, and personalizes support automatically. Achieving Invisible IT, the newest report in Lenovo’s ongoing Work Reborn series, explores how AI and automation are redefining the digital workplace and employee experience. Of the IT leaders who participated, 79% aspire to deliver seamless, proactive support that minimizes disruption for employees, but only 21% have achieved predictive issue resolution. The results underscore an urgent need for organizations t
Wasabi Launches Covert Copy, a Completely Invisible and Indestructible Copy of Data for a Higher Level of Cloud Storage Security2.12.2025 15:00:00 CET | Press release
Key takeaways:A patent pending innovation in data protection that affords the best protection yet from ransomwareEnables account managers to create a hidden, immutable copy of data that is invisible to anyone inside the corporate networkSupports wide range of compliance requirements across all industries Wasabi Technologies, the hot cloud storage company, has expanded its cyber resilient cloud storage capabilities with Covert Copy, a patent pending, advanced ransomware-resistant storage solution that allows users to create a locked, hidden copy of storage buckets to ensure critical data remains untouchable, even in the event of a cyberattack. The selected data is logically air gapped and cannot be seen, accessed, modified or deleted, without multi-user authentication approval, protecting it from any type of malicious attack. Covert Copy strengthens and simplifies traditional air gap strategies by creating a copy of data that is not only isolated, but unable to be detected at all. As th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom